Executives proposed two plans, one for Medicare Part B and one for Part D. Opposition to the newly proposed plans claim that the heavily biased proposals do not do enough to lower drug prices for patients, could cut pay for physicians, and would increase federal spending in most cases. To read the full article, click here.
The survey concluded that while voters approve of President Trump’s efforts to lower the cost of prescriptions, they are not in favor of rebates. When asked specifically about rebates, less than half of the respondents were in favor of the order. Similarly, when given more information about the implications of the executive order, +9% of respondents disapproved. To review the complete survey, click here.
The original research claimed that biologic substitutions should be used by pharmacists to reduce costs, but this comment argues that that is not enough at a federal level. To read the entire commentary on the proposed solutions, click here.
This letter comes in the wake of 5 major pharmaceutical companies announcing that they will be limiting their participation in the 340B program by restricting their discounts. To read the full 340B Health press release, click here.